Data registry to guide care for patients with COVID-19, blood cancers
ASH Research Collaborative’s Data Hub launched an international data registry to help inform care for individuals with blood cancers and COVID-19.
The ASH RC Data Hub COVID-19 Registry for Hematologic Malignancy is designed to facilitate sharing of near-real-time clinical data among health care providers who are caring for people with the novel coronavirus and either a current or prior blood cancer diagnosis.
“As the COVID-19 pandemic continues, lives depend on the global community urgently coming together to share their experiences,” ASH President Stephanie Lee, MD, associate director of the clinical research division and chair in cancer research at Fred Hutchinson Cancer Research Center, said in an ASH-issued press release. “[Although] we know people with cancer are more vulnerable to the virus, there is little understanding of how current or past treatment for hematologic malignancies changes that risk.”
The global registry includes de-identified patient data that health care providers enter using an online data collection tool on the ASH Research Collaborative website. The system is designed to capture the most critical information but also allow for quick data entry.
ASH Research Collaborative members will analyze data often and their reports will be publicly available.
“We encourage health care providers to start submitting their data through the COVID-19 Registry for Malignant Hematology website today and, shortly, to access reports for answers to their questions,” Lee said.
Clinicians may enter case data at www.ashresearchcollaborative.org/covid-19-registry.